Institute submits NDA for PET to diagnose Parkinsonian syndromes

11/15/2012 | MedicalXpress.com

The Feinstein Institute for Medical Research said it has submitted a new-drug application to the FDA for the use of 18F-fluorodopa-PET in diagnosing Parkinsonian syndromes. The FDA earlier this year approved the institute's use of the scan as part of an expanded access investigational new drug program.

View Full Article in:

MedicalXpress.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA